Forian Inc. (NASDAQ:FORA) Short Interest Down 11.3% in November

Forian Inc. (NASDAQ:FORA) was the target of a large drop in short interest in the month of November. As of November 30th, there was short interest totalling 132,400 shares, a drop of 11.3% from the November 15th total of 149,200 shares. Approximately 1.0% of the shares of the company are short sold. Based on an average trading volume of 17,100 shares, the short-interest ratio is presently 7.7 days.

Wall Street Analyst Weigh In

Separately, Roth Mkm restated a “buy” rating and set a $5.00 price target on shares of Forian in a report on Thursday, November 14th.

Institutional Investors Weigh In On Forian

Several institutional investors and hedge funds have recently made changes to their positions in the company. Elser Financial Planning Inc acquired a new position in Forian during the 2nd quarter worth approximately $1,885,000. Caprock Group LLC acquired a new stake in Forian in the second quarter valued at about $230,000. Finally, Canton Hathaway LLC boosted its stake in Forian by 2.3% in the third quarter. Canton Hathaway LLC now owns 269,650 shares of the company’s stock valued at $582,000 after buying an additional 6,125 shares in the last quarter. Institutional investors and hedge funds own 19.25% of the company’s stock.

Forian Stock Up 2.0 %

Shares of NASDAQ:FORA traded up $0.04 during trading on Tuesday, reaching $2.04. The stock had a trading volume of 18,522 shares, compared to its average volume of 16,417. Forian has a 52 week low of $1.97 and a 52 week high of $4.15. The firm has a market capitalization of $63.27 million, a price-to-earnings ratio of -22.22 and a beta of 1.07. The stock has a fifty day simple moving average of $2.07 and a two-hundred day simple moving average of $2.33.

Forian Company Profile

Forian Inc provides a suite of data management capabilities, and information and analytics solutions to optimize and measure operational, clinical, and financial performance for customers in the healthcare and related industries. It develops commercial, real world evidence (RWE), and market access solutions and proprietary data-driven insights, as well as offers data management solutions.